![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00093899 |
The purpose of this study is to assess the cholesterol lowering effects of an investigational drug in patients with mixed hyperlipidemia (high cholesterol and high triglycerides).
Condition | Intervention | Phase |
---|---|---|
Hyperlipidemia Hypercholesterolemia Hypertriglyceridemia |
Drug: ezetimibe (+) simvastatin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia |
Ages Eligible for Study: | 18 Years to 79 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2004_044, MK0653A-071 |
Study First Received: | October 7, 2004 |
Last Updated: | November 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00093899 |
Health Authority: | United States: Food and Drug Administration |
Mixed Hyperlipidemia |
Lipid Metabolism, Inborn Errors Hyperlipidemias Hypertriglyceridemia Metabolic Diseases Simvastatin Ezetimibe Procetofen Combined hyperlipidemia, familial |
Metabolism, Inborn Errors Genetic Diseases, Inborn Hyperlipidemia, Familial Combined Metabolic disorder Hypercholesterolemia Dyslipidemias Lipid Metabolism Disorders |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents |
Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |